Roivant Sciences Ltd. Common Shares

ROIVNASDAQUSD
28.17 USD
0.17 (0.58%)🟢LIVE (AS OF 11:26 AM EDT)
🟢Market: OPEN
Open?$28.06
High?$28.75
Low?$27.09
Prev. Close?$28.33
Volume?1.1M
Avg. Volume?5.8M
VWAP?$28.20
Rel. Volume?0.18x
Bid / Ask
Bid?$28.25 × 100
Ask?$28.26 × 200
Spread?$0.01
Midpoint?$28.26
Valuation & Ratios
Market Cap?20.3B
Shares Out?715.7M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?4.75
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?30.66Strong
Quick Ratio?30.66Strong
Cash Ratio?9.73Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score
58/100
P/E?
N/A
P/B?
4.75FAIR
P/S?
1,523.35HIGH
P/FCF?
N/A
EV/EBITDA?
-15.5CHEAP
EV/Sales?
1,412.29HIGH
Returns & Efficiency
ROE?
-19.0%WEAK
ROA?
-15.5%WEAK
Cash Flow & Enterprise
FCF?$-766855000
Enterprise Value?$18.8B
Related Companies
Loading...
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
750
Market Cap
20.3B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950